Physician profile
Daniel S Kantz
NPI 1205965563
$3,284.02
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $222 · 2021: $875 · 2022: $945 · 2023: $1,196 · 2024: $46.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,210.59 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $960.64 | 2021-2023 | |
| Novo Nordisk INC | $377.87 | 2020-2023 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $267.36 | 2021-2024 | Mounjaro, Trulicity |
| Pfizer INC. | $210.38 | 2020-2023 | |
| Glaxosmithkline, LLC. | $194.25 | 2020-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $157.22 | 2022-2023 | Spravato |
| Mylan Specialty L.P. | $150.77 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $123.40 | 2020-2024 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $104.78 | 2021-2023 | Trintellix |
| Amgen INC. | $91.24 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $79.89 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.00 | 2021-2023 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $70.10 | 2021-2022 | |
| Bausch Health US, LLC | $69.32 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $47.84 | 2023 | Gemtesa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $47.47 | 2022-2024 | Quviviq |
| Exact Sciences Corporation | $40.00 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company Ltd. | $38.74 | 2022 | |
| Abbott Laboratories | $28.64 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.09 | 2022 | |
| Merck Sharp & Dohme LLC | $27.58 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $23.85 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.99 | 2023 | Rexulti |
| Amarin Pharma, INC. | $18.61 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.71 | 2022 | |
| Supernus Pharmaceuticals, INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.